10% of People Are Genetically Resistant to GLP-1s — Here's What to Do Instead

The Stanford Study That Changes Everything

On April 10, 2026, Stanford Medicine published research in Genome Medicine revealing that roughly 10% of the general population carries genetic variants that make GLP-1 medications less effective at regulating blood sugar. The culprit: variants in the PAM gene (peptidylglycine alpha-amidating monooxygenase), which cause what researchers call "GLP-1 resistance."

Here's what's counterintuitive: people with these variants actually have higher levels of GLP-1 hormone in their blood — but it's less biologically active. The hormone is there. It just doesn't work as well. Dr. Anna Gloyn, professor of pediatrics and genetics at Stanford, led the decade-long international effort across human and mouse studies.

Does This Affect Weight Loss Too?

The Stanford study focused on blood sugar regulation, not weight loss. But the mechanism — impaired gastric emptying response to GLP-1 — is the same mechanism that drives appetite suppression and weight loss. Mice lacking the PAM gene showed faster gastric emptying that GLP-1 drugs couldn't slow down.

This maps to what clinicians see in practice. Estimates suggest 10–15% of people on Wegovy or Zepbound are "non-responders" for substantial weight loss. Some of that is behavioral. Some of it, we now know, may be genetic.

Why Tirzepatide Might Work When Semaglutide Doesn't

This is where the pricing comparison gets clinically relevant. Tirzepatide (Zepbound/Mounjaro) is a dual-agonist — it targets both GLP-1 and GIP receptors. If your GLP-1 pathway is genetically impaired, having a second mechanism of action isn't just a bonus — it might be the reason you respond to one drug but not the other.

In fact, researchers at the University of Munich published findings in April 2026 proposing that GIP and glucagon receptor activation alone — without GLP-1 targeting — may produce comparable weight loss at sufficient doses. The implication: for GLP-1-resistant patients, the GIP pathway could be doing the heavy lifting.

Can You Get Tested?

The PAM p.S539W variant can be detected through pharmacogenomic testing, but here's the reality: there's no widely available consumer test for GLP-1 resistance yet. The Stanford researchers suggest this could change — genetic testing could eventually help patients get on the right drug faster, avoiding months of ineffective treatment.

In the meantime, the practical signal is simpler: if semaglutide isn't working after 3–4 months at therapeutic dose, ask your provider about switching to tirzepatide. The dual mechanism may overcome what genetics are working against.

Switching Drugs: The Price Comparison

If you're considering a switch from semaglutide to tirzepatide, the cost difference matters. Here's where to find the best prices on both:

Even Non-Responders May Benefit

Perhaps the most important finding emerging in April 2026: GLP-1 medications appear to provide cardiovascular, anti-inflammatory, and liver health benefits independent of weight loss. A study led by Dr. Daniel Drucker showed that semaglutide improved markers of metabolic-associated steatohepatitis (MASH) regardless of whether participants lost weight.

If your insurance denied continued coverage because you didn't lose enough weight, these studies could be ammunition for an appeal. The clinical case for GLP-1 therapy is broadening well beyond the scale.